# Nanocrystalline Megestrol for Managing Chemotherapy-Induced Nausea and Vomiting

> **NCT07124195** · PHASE3 · NOT_YET_RECRUITING · sponsor: **The First Affiliated Hospital of Xinxiang Medical College** · enrollment: 126 (estimated)

## Conditions studied

- Malignant Solid Tumors
- Moderate to High Emetogenic Chemotherapy (MEC/HEC) Drugs

## Interventions

- **DRUG:** Medroxyprogesterone acetate oral suspension
- **COMBINATION_PRODUCT:** high antiemetic regimen
- **COMBINATION_PRODUCT:** moderate antiemetic regimen

## Key facts

- **NCT ID:** NCT07124195
- **Lead sponsor:** The First Affiliated Hospital of Xinxiang Medical College
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-08-10
- **Primary completion:** 2026-10-31
- **Final completion:** 2026-12-31
- **Target enrollment:** 126 (ESTIMATED)
- **Last updated:** 2025-08-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07124195

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07124195, "Nanocrystalline Megestrol for Managing Chemotherapy-Induced Nausea and Vomiting". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT07124195. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*